| Trial Name: |
MACM 1204
|
| Intro: |
A Dose Escalation Study of OncoGel® Treatment as an Adjunctive Therapy to External Beam Radiation in Patients with Inoperable Esophageal Cancer |
| Condition: |
|
| Description: |
This study is being done to determine to safety, tolerability and pharmacokinetics of OncoGel® injected directly into the tumor in patients with inoperable esophageal cancer who are also receiving external beam radiation therapy for palliation of dysphagia symptoms. The study medication, OncoGel® will be administered during endoscopy under standard conscious sedation techniques. OncoGel® dosing will occur at dosing day 1 on the same day or no more than 3 days prior to the time the patient receives external beam radiation therapy. Patients will receive external beam radiation once daily, 5 days a week, for 5.5 weeks. |
| Criteria: |
- Patients must have esophageal cancer that has been histologically or cytologically confirmed as adenocarcinoma or squamous cell carcinoma
- Patients must have surgically or medically inoperable esophageal cancer and be able to receive external beam radiation therapy at study dosages for palliation of symptoms
- Patient must have a minimum life expectancy of four months
- Patients must have a baseline dysphagia grade of 3, 4 or 5.
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back